Oral versus injection buprenorphine for opioid use disorder
Part of Mental health clinical trials.
This trial compares taking buprenorphine by mouth versus as an injection for opioid use disorder. It aims to see which option helps people stay on treatment and reduces opioid use over about a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’ve used opioids in the last 30 days, or started care in the last 30 days (like detox, hospital, or after jail)
- You are starting “MOUD” (medication for opioid use disorder) now, through a supervised clinic start of a buprenorphine product by mouth
- A structured interview says you have moderate to severe opioid use disorder
- You are seeking treatment for opioid use disorder and are willing to try a “partial-agonist” medication plan
- You can provide informed consent and participate in study visits for the active study period
- You can reach the buprenorphine maintenance dose range (about 4 mg to 32 mg by the study’s timeline, within 45 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications, methadone and buprenorphine, to see which helps people stay in treatment for opioid use disorder. You may be eligible if you are starting a new treatment episode.
This study tests a faster way to start buprenorphine (a medication for opioid use disorder) by using naloxone to briefly trigger mild withdrawal. This could help people get started on treatment more comfortably and quickly.
This study tests two different forms of buprenorphine (a medication for opioid addiction) to see which works better for people who use fentanyl or other strong synthetic opioids. If you are seeking treatment for opioid use, this trial may help you find the most effective option.
This trial tests whether starting buprenorphine using a low-dose plan is a safe and workable way to treat opioid use disorder. You may be able to join if you are 18+, have opioid use disorder, and can follow the study medication and visits.
This study compares two ways to start buprenorphine (a medicine for opioid use disorder) for people who use fentanyl daily. One group gets a low starting dose, the other gets a direct injection. The goal is to see which approach helps people stay in treatment longer.
This Phase 2 study compares a rapid way to start buprenorphine/naloxone versus the standard way, for people with opioid use disorder. It aims to see whether the faster start is safe and works well enough to help people begin treatment sooner.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.